2025-2030 Focus: • USP is in the process of revising the existing chapters such as <1663>, <1664>, <1664.1> besides completion leachable series chapters such as <1664.2>, <1664.3>, <1664.4>, <1664.5> 2025-2030 Key Issues • A major revision of <1664.1> Orally Inhaled and Nasal drug products (OINDPS) was published in PF 51(6) November 2025 and received substantial feedback from industry and regulators. USP is in the process of revising the existing chapter <1664.1> and need one or two experts who could contribute to the development of this chapter. Required Expertise Need strong industry expertise to fulfill this chapter revision requirements. Based on the E&L Subcommittee recommendation, reached out to IPAC-RS consortium to get appropriate expertise to complete this chapter development.